SCHEMBL7623713

SCHEMBL7623713

CS(=O)(=O)Nc1ccc(OP(Oc2ccc(NS(C)(=O)=O)cc2)Oc2ccc(NS(C)(=O)=O)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.59
LMNA P02545 3/20 0.54
MAPK1 P28482 2/20 0.54
GAA P10253 1/20 0.54
KIF11 P52732 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KEAP1 Q14145 1/20 0.52
HPGD P15428 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 1/20 0.52
HTT P42858 1/20 0.52
AR P10275 1/20 0.51
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
RECQL P46063 1/20 0.45
NR3C2 P08235 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4205144 0.81 PGR (0.85) PGRLMNAMAPK1GAAKIF11
SCHEMBL12054668 0.80 KEAP1 (0.75) PGRLMNAMAPK1GAAKIF11
SCHEMBL171658 0.79 LMNA (0.79) PGRLMNAMAPK1GAAKIF11
SCHEMBL3112491 0.78 PGR (0.73) PGRLMNAMAPK1GAAKIF11
SCHEMBL15387008 0.78 PGR (0.61) PGRLMNAMAPK1GAAKIF11
SCHEMBL7368274 0.78 PGR (0.61) PGRLMNAMAPK1GAAKIF11
SCHEMBL82733 0.76 CA1 (0.64) PGRLMNAKIF11KEAP1HPGD
SCHEMBL321265 0.76 PGR (0.59) PGRLMNAMAPK1GAAKIF11
SCHEMBL4668688 0.74 LMNA (0.72) PGRLMNAMAPK1GAAKIF11
SCHEMBL8499712 0.74 PGR (0.58) PGRLMNAMAPK1GAAKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020061839-A1 Serine peptidase modulators SCHARPE SIMON LODEWIJK (BE) 2002-05-23 US disclosed
EP-1062222-A1 SERINE PEPTIDASE MODULATORS Fondatech Benelux N.V. (BE) 2000-12-27 EP disclosed
WO-1999046272-A1 SERINE PEPTIDASE MODULATORS FONDATECH BENELUX N.V. (BE) 1999-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061839-A1 Serine peptidase modulators FAP, CTSC, DPP4 PGR 4026/4885LMNA 3159/4885MAPK1 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.